Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Legislation Regulation topic
No spam. Unsubscribe anytime.
Board refines legislation and regulation goals, debates wording on 'advocacy' and scope of unregulated care
Summary
At a June 10 strategic-planning session, the California State Board of Pharmacy approved revised goal-area language for legislation and regulation, debated whether to ‘advocate’ or more actively ‘pursue’ statutory and regulatory changes, and asked staff to refine objectives addressing unregulated care settings, standard-of-care definitions, telehealth and emerging technologies.
The California State Board of Pharmacy on June 10 approved a revised description for its legislation and regulation goal area while members debated how assertive the board’s language should be when describing its role.
Board facilitators presented a suggested statement that the board “advocates for statutes, regulations, and procedures that support the board’s mandate.” Several members said the word “advocates” sounded too passive and suggested wording that would allow the board both to pursue changes and respond to outside legislation. The group kept the suggested text for further offline refinement and marked it as accepted for the draft strategic plan.
The board discussed several objectives tied to that goal area. Members identified strengths—clear legislative communications and consumer-protection focus—and areas for improvement including unclear or overlapping regulations, the need for greater engagement with legislators and stakeholders, and several carry‑over items from the sunset-review and prior plans (e.g., regulation of IV hydration clinics, pharmacist-to-technician ratios and AI-related rules).
A recurring thread was how to describe and respond to services that operate outside traditional pharmacy oversight. Members questioned the label “wellness clinics,” arguing for broader language such as “unregulated pharmaceutical care” or terms that focus on activity (e.g., medication administration) rather than place. The group agreed to work offline to finalize terminology so the board’s objectives do not appear to encroach on other healing‑arts boards’ jurisdictions.
On scope and practice, several members recommended moving from lists of enumerated limitations to a broader “standard of care” statement defined by safety, legality and ethics. That approach, members said, would allow the board to cover future practice innovations—one member cited inhaled GLP‑1 agents as an example—without repeated rule changes.
Members also directed staff to review regulations for opportunities to streamline and clarify which rules apply to which practice settings, noting that some tasks might belong with the licensing committee or communications teams depending on their operational focus.
The board’s discussion included telehealth and emerging technologies, with members noting overlap between regulatory authority and education/outreach responsibilities. Participants asked staff to draft objectives that address technologies that either “alter” practice or “bypass” pharmacy authority, and to include options for seeking regulatory or statutory action when appropriate.
The strategic-planning work on legislation and regulation will be finalized by staff for presentation at a subsequent board meeting, after which action planning will assign tasks, responsible staff, due dates and performance measures.
